menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass. , May 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (”Intellia Therapeutics” or “Intellia”) a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of its initial public
Read More

Intellia Therapeutics Appoints Perry Karsen as Chairman of its Board of Directors

CAMBRIDGE, MASS. – April 22, 2016 — Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors. Mr. Karsen held leadership positions at Celgene Corporation, including Chief Operations Officer and Executive Vice President and
Read More

Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics

Tarrytown, New York and Cambridge, Mass. (April 11, 2016) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene editing technology for in vivo therapeutic development.
Read More

Intellia Founders Awarded Distinguished Alpert Prize

BOSTON, MA – March 9, 2016 – Harvard Medical School announced today that the2016 Warren Alpert Foundation Prize will be awarded to five scientists for the novelgene-editing technology, CRISPR/Cas9. Two of Intellia Therapeutics' founders, Jennifer Doudna and Rodolphe Barrangou , are included among
Read More

Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/CAS9

Focused on Immuno-Oncology, Autoimmune and Inflammatory Disease Areas Dedicated Scientific Organization and Leadership Team Will Build on Intellia's Expertise with CRISPR/Cas9 – Cambridge, Mass. – January 12, 2016 – Intellia Therapeutics, a leading gene-editing company, has launched a new division,
Read More

Intellia Therapeutics Appoints Caroline Dorsa To Company’s Board Of Directors

Former Chief Financial Officer Brings 30 Years of Business Leadership and Board of Directors' Experience CAMBRIDGE, MASS. – December 14, 2015 — Intellia Therapeutics, Inc., a leading gene-editing company, has named Caroline Dorsa to its Board of Directors .
Read More

Joint Statement of Intellia Therapeutics & CRISPR Therapeutics: Position Regarding Human Germline Gene Editing

Therapeutic applications of gene editing, including CRISPR/Cas9 and other CRISPR-based technologies, provide an unparalleled opportunity for treating, or even curing, patients with serious genetic disorders. These exciting, recently discovered technologies have the potential to bring new treatments
Read More

FierceBiotech names Intellia Therapeutics as one of its “Fierce 15” Biotech Companies of 2015

Cambridge, MA – September 30, 2015 – Intellia Therapeutics has been named by FierceBiotech as one of 2015's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. "We're honored to be named to the 2015 "Fierce 15" Biotech
Read More

Intellia Therapeutics Secures $70 Million in Series B Financing

Funds to Accelerate Discovery and Development of Curative Products Based on CRISPR/Cas9 Gene-Editing Technology Pipeline Primarily Focused on Disorders of the Liver and Blood CAMBRIDGE, Mass., Sept. 1, 2015 – Intellia Therapeutics, a leading gene-editing company focused on the development of
Read More

Intellia Statement on Germline Editing

In May, both the National Institutes of Health (NIH) and the White House voiced concern over ethical issues associated with using gene-editing technology to alter the human germline. The White House Office of Scientific Assessment further stated that, "the Administration believes that altering the
Read More
RSS FEEDS
PRINT PAGE